2型糖尿病患者对10价肺炎球菌结合疫苗(PCV10)的体液免疫应答
这项先导研究纳入40名成人(24例2型糖尿病、16例无2型糖尿病),接种PCV10后用WHO参考ELISA和MOPA检测血清型特异性IgG浓度与调理吞噬杀伤功能。两组接种后IgG和调理滴度均较基线显著升高,但2型糖尿病组对血清型19F和9V的应答显著低于年龄性别匹配的非糖尿病者,且8个月时下降更快。
要点
- 2型糖尿病组接种PCV10后对血清型19F和9V的IgG浓度与调理滴度显著低于年龄性别匹配的非糖尿病对照。
- 两组接种后IgG浓度与调理滴度较基线均显著升高,最高IgG浓度均见于T2(1个月)的血清型19F。
- 2型糖尿病组8个月时血清型特异性IgG浓度快速下降;肥胖糖尿病者IgG浓度低于非肥胖2型糖尿病者。
核心结论
- 2型糖尿病个体对PCV10产生显著的保护性体液免疫应答,但应答相对较弱且下降更快。
研究设计与样本
- 先导研究共纳入40名成人,其中24例患2型糖尿病、16例无2型糖尿病,均接种PCV10。
- 采用WHO参考ELISA和多重调理吞噬杀伤试验(MOPA)检测基线及接种后14天、1个月、8个月的血清型特异性IgG浓度与功能。
主要发现
- 接种后14天、1个月和8个月,2型糖尿病组与非糖尿病组的IgG几何平均浓度和调理滴度均较基线显著升高。
- 两组接种后IgG浓度最高均见于1个月时的血清型19F。
- 接种后2型糖尿病组对血清型19F和9V的IgG浓度和调理滴度显著低于年龄性别匹配的非糖尿病个体。
- 2型糖尿病组接种后8个月血清型特异性IgG浓度快速下降。
- 肥胖的2型糖尿病个体IgG浓度低于非肥胖的2型糖尿病个体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal infections pose a significant health problem in individuals with comorbid conditions such as Type 2 diabetes mellitus. Although pneumococcal vaccines are recommended in individuals with type 2 diabetes, there is a lack of data on the immunogenicity of pneumococcal vaccines in the type 2 diabetes population. This pilot study was therefore developed to determine if the humoral immune response to the 10-valent pneumococcal conjugate vaccine (PCV10) in those with and without type 2 diabetes is comparable. METHODS: A total of 40 (24 with type 2 diabetes and 16 without type 2 diabetes) adults were immunized with PCV10. WHO reference ELISA and multiplexed opsonophagocytic killing assay (MOPA) were used to measure the concentration and functionality of serotype-specific IgG at baseline and 14 days, 1 month, and 8 months post-vaccination. RESULTS: The geometric mean IgG concentrations and opsonic titers increased significantly in post-immunization (T1-14 days, T2-1 month, and T3-8 month) serum samples compared to baseline (T0) in individuals with and without type 2 diabetes. In both groups, the highest post-immunization IgG concentrations were measured for serotype 19F at T2. Individuals with type 2 diabetes showed significantly lower IgG concentrations and opsonic titers for serotype 19F and 9V post-immunization compared to age and sex-matched non-diabetes individuals. Serotype-specific IgG concentrations declined rapidly in those with type 2 diabetes at 8 months post-immunization. Obese diabetes individuals had lower IgG concentrations compared to non-Obese individuals with type 2 diabetes. CONCLUSION: Individuals with type 2 diabetes demonstrated a significant protective humoral immune response to the 10-valent pneumococcal conjugate vaccine (PCV10); however, the response was comparatively less robust and declined faster in those with type 2 diabetes compared to age and sex-matched non-diabetes controls.
引用
- Ahmad I, Burton R, Arshad R, et al. Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus. Vaccine. 2025. PMID: 40127571. doi:10.1016/j.vaccine.2025.127029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。